GERN Share Price Performance
US$1.40
-0.19 (-11.95%)
58.8% undervalued intrinsic discount
US$3.40
Fair Value
Price US$1.40
AnalystConsensusTarget US$3.40
AnalystLowTarget US$1.00
AnalystHighTarget US$5.00
Fair ValueUS$3.40
Share Pricen/a
Geron Corporation Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 50 Fair Values set on narratives written by author
GERN Community Narratives
AN
Fair Value US$3.4 58.8% undervalued intrinsic discount
Aging Population Trends Will Expand Hematology Market Opportunity
1users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
Fair Value US$1 40.0% overvalued intrinsic discount
Drug Pricing Controls And Approval Delays Will Curb Viability
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$5 72.0% undervalued intrinsic discount
Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets
Key Takeaways Rapid uptake of RYTELO, strategic partnerships, and superior commercial execution could drive revenue and market share beyond current expectations. Strong leadership, financial resources, and innovative therapies position Geron for pipeline advancement and long-term value creation in a growing market.Read more
168
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$5
72.0% undervalued intrinsic discount
Fair Value
Profit Margin
54.51%
Future PE
9.33x
Price in 2029
US$6.17
Aging Population Trends Will Expand Hematology Market Opportunity
Key Takeaways Expanding patient pool, strong adoption, and premium pricing position Geron for sustained revenue growth and robust margins. Pipeline advances, regulatory progress, and industry partnerships create significant opportunities for multi-geography growth and shareholder value.Read more
495
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
US$3.4
58.8% undervalued intrinsic discount
Fair Value
Profit Margin
22.97%
Future PE
24.72x
Price in 2029
US$4.19
Drug Pricing Controls And Approval Delays Will Curb Viability
Key Takeaways Overdependence on a single product and rising competition threaten revenue stability and long-term market share. Stricter global pricing, regulatory pressures, and challenging funding conditions may constrain growth, margins, and future innovation.Read more
25
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$1
40.0% overvalued intrinsic discount
Fair Value
Profit Margin
16.25%
Future PE
12.96x
Price in 2028
US$1.22
Trending Discussion
Recently Updated Narratives
AN
GERN: Future Myeloid Franchise And 2026 Revenue Guidance Will Support Upside
Fair Value: US$5 72.0% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GERN: Future Profit Upside Will Be Supported By Conservative Forecast Reset
Fair Value: US$3.4 58.8% undervalued intrinsic discount
23 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Drug Pricing Controls And Approval Delays Will Curb Viability
Fair Value: US$1 40.0% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Geron Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.13
- 97.42%
- -45.41%
- 52.9%
About GERN
- Founded
- 1990
- Employees
- 258
- CEO
- WebsiteView website
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
